Viatris Inc. (VTRS)
Automate Your Wheel Strategy on VTRS
With Tiblio's Option Bot, you can configure your own wheel strategy including VTRS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol VTRS
- Rev/Share 12.0069
- Book/Share 13.1251
- PB 0.6636
- Debt/Equity 0.9238
- CurrentRatio 1.6822
- ROIC -0.0935
- MktCap 10222752800.0
- FreeCF/Share 1.5592
- PFCF 5.4985
- PE -2.7402
- Debt/Assets 0.3758
- DivYield 0.0551
- ROE -0.206
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 5
- P/B Score 4
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | VTRS | Goldman | -- | Neutral | -- | $10 | June 6, 2025 |
News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viatris Inc. - VTRS
Published: February 27, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 27, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Viatris Inc. ("Viatris" or the "Company") (NASDAQ:VTRS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
Viatris Q4 Earnings and Revenues Miss Estimates, Stock Plunges
Published: February 27, 2025 by: Zacks Investment Research
Sentiment: Negative
VTRS Q4 earnings and sales miss estimates. The guidance for 2025 looks disappointing due to the financial impact of the Indore facility warning letter and import alert.
Read More
Viatris Inc. (VTRS) Q4 2024 Earnings Call Transcript
Published: February 27, 2025 by: Seeking Alpha
Sentiment: Neutral
Viatris Inc. (NASDAQ:VTRS ) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Bill Szablewski - Head of Capital Markets Scott Smith - CEO Philippe Martin - Chief R&D Officer Doretta Mistras - CFO Corinne Le Goff - Chief Commercial Officer Conference Call Participants David Amsellem - Piper Sandler Ashwani Verma - UBS Chris Schott - JPMorgan Jason Gerberry - Bank of America Umer Raffat - Evercore Balaji Prasad - Barclays Operator Good morning everyone and welcome to the Viatris Q4 and Full Year 2024 Earnings Call. All participants will be in the listen-only mode.
Read More
Viatris: One Swallow Doesn't Make A Summer
Published: February 27, 2025 by: Seeking Alpha
Sentiment: Negative
Viatris Inc. missed estimates on sales and earnings per share. The company's 2025 guidance reveals significant challenges, including a $385 million EBITDA hit from issues at the Indore plant. We would stay out of VTRS stock.
Read More
Viatris (VTRS) Q4 Earnings and Revenues Lag Estimates
Published: February 27, 2025 by: Zacks Investment Research
Sentiment: Negative
Viatris (VTRS) came out with quarterly earnings of $0.54 per share, missing the Zacks Consensus Estimate of $0.57 per share. This compares to earnings of $0.61 per share a year ago.
Read More
Idorsia and Viatris update their collaboration for selatogrel and cenerimod
Published: February 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
Ad hoc announcement pursuant to Art. 53 LR Idorsia's contribution to the development costs reduced by USD 100 million Viatris potential regulatory and sales milestones payments to Idorsia reduced by USD 250 million Allschwil, Switzerland – February 26, 2025 Idorsia Ltd (SIX: IDIA) today announced that it has reached an agreement with Viatris Inc. (NASDAQ: VTRS) to update the terms of the global development and commercialization collaboration for selatogrel and cenerimod.
Read More
What's in Store for These 5 Biotech Stocks This Earnings Season?
Published: February 24, 2025 by: Zacks Investment Research
Sentiment: Neutral
Let's look at five biotech and drug companies, VTRS, PRGO, NVAX, NTLA and IOVA, slated to release their fourth-quarter 2024 results on Feb. 27, 2025.
Read More
What's in the Cards for Viatris Stock This Q4 Earnings?
Published: February 21, 2025 by: Zacks Investment Research
Sentiment: Positive
VTRS' Q4 results are likely to gain from new product launches in all major geographies.
Read More
About Viatris Inc. (VTRS)
- IPO Date 1980-03-17
- Website https://www.viatris.com
- Industry Drug Manufacturers - Specialty & Generic
- CEO Mr. Scott Andrew Smith Ph.D.
- Employees 32000